Buy Crizocent 250 MG (Crizotinib) - Mediaid pharmacy

Crizocent 250 MG (Crizotinib)

Product Name : Crizocent
Generic Name : Crizotinib
Formulation : Capsule
Available Pack Size : 4’s
Available Strengths : 250 mg
Registrations : Export Only

Message Us on WhatsApp

Product Information

Crizocent (Crizotinib) 250mg is a selective ALK, ROS1, and MET tyrosine kinase inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) whose tumours are ALK-positive or ROS1-positive, as well as certain ALK-positive inflammatory myofibroblastic tumours (IMT) and ALK-positive anaplastic large cell lymphoma (ALCL). It works by blocking abnormal ALK, ROS1, and MET signalling that drives the growth and survival of tumour cells carrying these gene rearrangements. Global supplier: Mediaid Pharmacy with worldwide shipping.

Basic Product Information of Crizocent (Crizotinib) 250mg

Brand Name	Crizocent (Crizotinib)
Generic Name	Crizotinib INN
Drug Class	ALK / ROS1 / MET Tyrosine Kinase Inhibitor
Available Strengths	250mg
Formulation	Capsule
Pack Size	4 Capsules per Pack. The standard regimen requires 2 capsules daily (500mg/day), so continuous therapy requires multiple packs.
Primary Indication	ALK-Positive or ROS1-Positive Metastatic NSCLC, ALK-Positive IMT, ALK-Positive ALCL
Regulatory Approvals	USFDA Approved (ALK/ROS1-positive NSCLC, ALK-positive IMT, ALK-positive ALCL). EMA Approved (ALK/ROS1-positive NSCLC).
Originator Brand	Xalkori by Pfizer
Manufacturer	[Manufacturer name to be confirmed], Bangladesh
Global Supplier	Mediaid Pharmacy, Worldwide Shipping Available
Registration	Export Only
Storage Conditions	Store below 30 degrees Celsius. Keep in a dry place away from light and moisture. Keep out of the reach of children.

How Crizocent (Crizotinib) Works

Crizocent contains Crizotinib, an inhibitor of receptor tyrosine kinases including ALK (anaplastic lymphoma kinase), ROS1, MET (c-Met/HGFR), and RON. In certain cancers, chromosomal translocations create abnormal fusion genes such as EML4-ALK, producing oncogenic fusion proteins that drive continuous, unregulated tumour cell growth and survival signalling.

Crizotinib works by binding to the ATP-binding pocket of these kinases, blocking their enzymatic activity and interrupting the downstream signalling cascades that these fusion proteins rely on for tumour proliferation. This targeted mechanism allows Crizocent to selectively act on cancer cells driven by ALK or ROS1 rearrangements while sparing normal tissue that does not depend on these pathways.

Crizocent is an oral capsule taken twice daily, offering a convenient, biomarker-guided treatment option for patients whose tumours have been confirmed as ALK-positive or ROS1-positive by an approved diagnostic test.

Indications for Crizocent (Crizotinib)

Crizocent (Crizotinib) is indicated for the following conditions:

ALK-Positive Metastatic NSCLC

For adult patients with metastatic non-small cell lung cancer whose tumours are ALK-positive, as detected by an approved diagnostic test, as a first-line or subsequent treatment option.

ROS1-Positive Metastatic NSCLC

For adult patients with metastatic non-small cell lung cancer whose tumours are ROS1-positive, a distinct molecular subset for which Crizotinib was among the first approved targeted therapies.

ALK-Positive Inflammatory Myofibroblastic Tumour

For adult and paediatric patients 1 year and older with unresectable, recurrent, or refractory ALK-positive IMT, a rare soft-tissue tumour.

ALK-Positive Anaplastic Large Cell Lymphoma

For paediatric patients 1 year and older and young adults with relapsed or refractory, systemic ALK-positive ALCL.

Benefits of Crizocent (Crizotinib) 250mg

Biomarker-Guided Precision Therapy

Crizocent selectively targets tumours driven by ALK or ROS1 gene rearrangements, offering a precision treatment approach for molecularly defined lung cancer subtypes.

Multi-Indication Oncology Use

Approved for ALK/ROS1-positive NSCLC as well as ALK-positive IMT and ALCL, giving physicians a versatile targeted therapy across several tumour types.

Convenient Oral Capsule

Taken as a twice-daily oral capsule, Crizocent avoids the infusion visits associated with intravenous chemotherapy, supporting treatment at home.

Affordable Alternative to Xalkori

Crizocent contains the same active ingredient as Xalkori by Pfizer, at a significantly lower cost, improving access to targeted lung cancer therapy.

NCCN-Recognised First-Line Option

Crizotinib is recognised in international treatment guidelines as a first-line option for ROS1-positive and ALK-positive metastatic NSCLC.

WHO-GMP and cGMP Certified

Manufactured under strict WHO-GMP, cGMP, and ISO-certified standards, ensuring every batch of Crizocent meets consistent quality, safety, and efficacy requirements.

How to Take Crizocent (Crizotinib)

Route: Oral, taken by mouth

Standard dose: 250mg (one capsule) taken orally twice daily, approximately 12 hours apart, continued until disease progression or unacceptable toxicity.

With food: Can be taken with or without food. Avoid grapefruit, grapefruit juice, and Seville oranges during treatment.

Missed or vomited dose: If a dose is missed, take it as soon as remembered unless the next scheduled dose is due within a few hours, in which case skip the missed dose. If vomiting occurs after a dose, do not take an extra dose; simply take the next dose at the regular scheduled time.

Hepatic impairment: No adjustment needed for mild impairment. Moderate impairment (total bilirubin greater than 1.5 to 3 times ULN): 200mg twice daily. Severe impairment (total bilirubin greater than 3 times ULN): 250mg once daily.

Renal impairment: No adjustment needed for mild or moderate impairment. Severe impairment (creatinine clearance below 30 mL per minute) not requiring dialysis: starting dose of 250mg once daily, which may be increased to 200mg twice daily after at least 4 weeks based on tolerability.

Swallowing: Swallow capsules whole with a glass of water. Do not open, break, or chew the capsules.

Paediatric use: Established for ALK-positive IMT and ALK-positive ALCL in patients 1 year and older, using body-surface-area-based dosing. Not established for NSCLC in children.

Prescription Medication. Crizocent should only be initiated and monitored by an oncologist or specialist physician after confirmed ALK or ROS1 positivity by an approved test. Baseline and periodic liver function tests, ECG for QT interval, and eye examinations are required. Always follow your prescribing physician’s exact instructions.

Monitoring and Dosage Adjustments

Regular monitoring is essential during Crizocent treatment. Your healthcare provider will monitor liver function tests for hepatotoxicity, an ECG for QT interval prolongation, heart rate for bradycardia, and renal function given reported decreases in eGFR with Crizotinib. Monitoring also includes assessment for vision changes, respiratory symptoms that could indicate interstitial lung disease or pneumonitis, and abdominal pain that could indicate gastrointestinal perforation. Report any new visual disturbances, shortness of breath, palpitations, or severe abdominal pain to your doctor immediately.

Drug Interactions and Important Information

Crizotinib is metabolised primarily by CYP3A. Avoid concomitant use of strong CYP3A inhibitors such as ketoconazole, itraconazole, clarithromycin, and ritonavir, as these can significantly increase Crizotinib plasma levels. Avoid strong CYP3A inducers such as rifampin, carbamazepine, phenytoin, and St. John’s Wort, as these can reduce Crizotinib efficacy.

Crizotinib itself is a moderate CYP3A inhibitor and may increase the levels of other CYP3A-metabolised medications with a narrow therapeutic range, such as certain immunosuppressants, ergot derivatives, and antiarrhythmics. Avoid co-administration with other QT-prolonging medications. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Crizocent.

Side Effects and Precautions

Common Side Effects

Vision disorders (blurred vision, light flashes, floaters)

Nausea and vomiting

Diarrhoea and constipation

Oedema (swelling)

Elevated liver enzymes

Fatigue and decreased appetite

Dizziness and taste alteration

Upper respiratory tract infections

Serious Warnings and Precautions

Hepatotoxicity. Regular liver function monitoring is required.

Interstitial lung disease / pneumonitis, which can be severe or fatal.

QT interval prolongation and bradycardia. Use with caution with other QT-prolonging drugs.

Severe or sudden loss of vision. Report any significant vision change immediately.

Gastrointestinal perforation. Report severe abdominal pain immediately.

Renal cysts and decreased renal function.

Not recommended during pregnancy or breastfeeding; embryo-fetal toxicity.

Who Should Use Crizocent (Crizotinib)?

Crizocent is suitable for adult patients diagnosed with metastatic NSCLC confirmed as ALK-positive or ROS1-positive by an approved diagnostic test, and adult and eligible paediatric patients with ALK-positive inflammatory myofibroblastic tumour or ALK-positive anaplastic large cell lymphoma. It is prescribed by oncologists and specialist physicians experienced in biomarker-driven cancer therapy. Confirmed biomarker testing, baseline liver function, ECG, and eye examination are required before initiating treatment.

Manufacturer

Crizocent (Crizotinib) is manufactured in Bangladesh under strict WHO-GMP, cGMP, and ISO-certified standards for export markets, offering an affordable and bioequivalent alternative to Xalkori by Pfizer at a fraction of the cost. [Please confirm the exact manufacturer name so it can be added here and in the specs table above.]

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty oncology medications. We ensure Crizocent (Crizotinib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Crizocent (Crizotinib) from Mediaid Pharmacy?

Crizocent represents an important biomarker-driven treatment option for patients with ALK-positive or ROS1-positive cancers. As the generic equivalent of Xalkori by Pfizer, it delivers the same active ingredient, Crizotinib, with the same proven kinase inhibition mechanism at a dramatically more affordable price. Manufactured under WHO-GMP and cGMP standards and distributed globally by Mediaid Pharmacy, Crizocent gives patients worldwide access to high-quality targeted oncology therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Crizotinib option with worldwide delivery, Crizocent from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Crizocent (Crizotinib)

What is Crizocent (Crizotinib) used for?

Crizocent (Crizotinib) is a targeted kinase inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) whose tumours are ALK-positive or ROS1-positive, as well as ALK-positive inflammatory myofibroblastic tumour (IMT) and ALK-positive anaplastic large cell lymphoma (ALCL). It works by blocking the abnormal signalling that these gene rearrangements use to drive tumour growth.

How should I take Crizocent (Crizotinib)?

Crizocent is taken orally as one 250mg capsule twice daily, about 12 hours apart, with or without food. Dose reductions apply for patients with hepatic or renal impairment. Always follow your prescribing physician’s exact instructions and do not stop or change your dose without medical advice.

What strength and pack size is Crizocent (Crizotinib) available in?

Crizocent is available as a 250mg capsule, supplied in packs of 4 capsules. Since the standard regimen is 2 capsules per day, one pack covers 2 days of treatment; patients should plan to order enough packs to maintain continuous, uninterrupted therapy.

Is Crizocent the same as Xalkori (Crizotinib by Pfizer)?

Yes. Crizocent is the generic equivalent of Xalkori. Both contain the same active ingredient, Crizotinib, in the same dosage form and strength. Crizocent delivers the same clinical benefits as Xalkori at a significantly lower cost, making it a more accessible option for patients worldwide.

What are the side effects of Crizocent (Crizotinib)?

Common side effects include vision disturbances, nausea, diarrhoea, oedema, elevated liver enzymes, and fatigue. Serious but less common risks include hepatotoxicity, interstitial lung disease, QT interval prolongation, severe vision loss, and gastrointestinal perforation. Always consult your physician for a complete assessment of your individual risks and benefits before starting treatment.

Can Crizocent be taken with other medications?

Strong CYP3A inhibitors and inducers can significantly affect Crizotinib levels and should be avoided. Crizotinib itself can also raise the levels of certain other medications metabolised by CYP3A. Always review your complete medication list, including supplements and herbal products, with your prescribing physician before starting Crizocent.

Is Crizocent (Crizotinib) safe during pregnancy or breastfeeding?

No. Crizocent is not recommended during pregnancy or breastfeeding due to the risk of embryo-fetal toxicity. Women of childbearing potential must use effective contraception during treatment and for a period after the final dose as advised by their physician. Please consult your physician before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding.

Can I order Crizocent (Crizotinib) online with worldwide shipping?

Yes. Mediaid Pharmacy supplies Crizocent (Crizotinib) 250mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.

Order Crizocent (Crizotinib) 250mg with Worldwide Shipping

Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com

Message on WhatsApp